Artivion Q3 rev $113.4M (+18% YoY), net income $6.5M; raises FY guidance

ARTIVION, INC.

2025-Q3 EPS reported $0.16 revenue$325,338,000

Revenue $113.4M, up 18% GAAP/16% constant currency YoY; net income $6.5M ($0.13 EPS) vs loss of $2.3M.
Adjusted EBITDA $24.6M, up 39% from $17.7M; non-GAAP EPS $0.16 vs $0.12.
Stent grafts +38%, On-X +25%, preservation +5%, BioGlue +2% YoY.
Enrolled first patient in ARTIZEN IDE trial for Arcevo; refinanced credit to 2031 with $150M delayed draw.
Raises FY 2025 revenue guidance to $439-$445M (prev $435-$443M) and EBITDA to $88-$91M (prev $86-$91M).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.